Ascendis Pharma ADR (NQ: ASND )
138.45
+0.51
(+0.37%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Headline News about Ascendis Pharma ADR
![](https://cdn.benzinga.com/files/images/story/2024/08/13/Movers.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/08/12/Genetic-Research-And-Biotech-Science-Con_0.jpeg?width=1200&height=800&fit=crop)
![](https://www.investors.com/wp-content/uploads/2018/01/Stock-drugs-10-adobe.jpg)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2024/07/05/tech-stocks.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop)
(ASND) - Analyzing Ascendis Pharma's Short Interest
May 28, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2024/05/15/ASND.png?width=1200&height=800&fit=crop)
FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months
May 15, 2024
Via Benzinga
Exposures
Product Safety
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
![](https://investorplace.com/wp-content/uploads/2022/05/earnings-season-1600.png)
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_18.jpeg?width=1200&height=800&fit=crop)
Looking Into Ascendis Pharma's Recent Short Interest
April 26, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop)
![](https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg)
![](https://cdn.benzinga.com/files/images/story/2024/03/03/shutterstock_131733137.jpg?width=1200&height=800&fit=crop)
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop)
$1000 Invested In This Stock 15 Years Ago Would Be Worth $45,000 Today
February 23, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop)
How Is The Market Feeling About Ascendis Pharma?
February 13, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_1.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/earnings_image.jpeg?width=1200&height=800&fit=crop)
![](/next-assets/images/schema-image-default.png)
Ascendis Pharma's Earnings: A Preview
February 06, 2024
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/valuestock_image_3.jpeg?width=1200&height=800&fit=crop)
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/12/19/asnd.png?width=1200&height=800&fit=crop)
Ascendis Pharma's Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial
December 19, 2023
Via Benzinga
![](https://cdn.benzinga.com/files/images/story/2023/analyst_ratings_image_1.jpeg?width=1200&height=800&fit=crop)
Analyst Expectations for Ascendis Pharma's Future
November 09, 2023
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.